Fresenius SE

Investor News 2006

19.12.2006Fresenius ProServe focuses on hospital business – agreement reached on the sale of Pharmaplan GmbH
PDF Text as PDF-File
18.12.2006Phase II/III pivotal study with trifunctional antibody removab® shows encouraging results in malignant ascites
PDF Text as PDF-File
04.12.2006Shareholders approve conversion of Fresenius AG into a European Company (SE) and share split at Extraordinary General Meeting
21.11.2006European Commission grants Orphan Drug Designation for the removab® antibody to treat gastric cancer
PDF Text as PDF-File
31.10.2006First nine months 2006: Excellent sales and earnings growth in all business segments – Strong third quarter – Outlook raised
(for additional tables please see pdf-file)
PDF Text as PDF-File
11.10.2006Fresenius plans conversion of Fresenius AG into European Company (SE) and share split
PDF Text as PDF-File
11.09.2006HELIOS obtains antitrust approval to acquire HUMAINE Kliniken
PDF Text as PDF-File
03.08.2006First half 2006:
Firmly on growth track; excellent operating performance in all segments; full-year sales and earnings forecast raised (for additional tables please see pdf-file)
PDF Text as PDF-File
23.06.2006Fresenius Biotech Reports Encouraging Phase IIa Results for its Trifunctional Antibody Removab in Ovarian Cancer Patients: Higher Dose Regimen Improves Tumor Response Without Affecting Good Tolerability
PDF Text as PDF-File
03.05.2006First quarter 2006:
Extremely strong start into fiscal year 2006 (for additional tables please see pdf-file)
PDF Text as PDF-File
04.04.2006Fresenius Biotech and Nabi Biopharmaceuticals sign agreement for the clinical development and the marketing of ATG Fresenius S in the U.S.
PDF Text as PDF-File
30.03.2006Fresenius redeems remaining amount of € 300 million Series A Senior Notes
PDF Text as PDF-File
20.03.2006Fresenius Continues expansion in the German hospital market and agrees to acquire the HUMAINE Kliniken
PDF Text as PDF-File
22.02.2006Fiscal Year 2005: Excellent sales and earnings growth
13th consecutive dividend increase proposed
Outlook 2006: Sales of approx. € 10.5 billion and net income growth of more than 30 % expected (for additional tables see pdf-file)
PDF Text as PDF-File
13.01.2006Fresenius AG announces pricing of €1 billion bond issue and successful completion of tender offer
PDF Text as PDF-File
13.01.2006Fresenius AG Closes Debt Tender Offer
06.01.2006Enzon and Fresenius end agreement for development and marketing of ATG-Fresenius S in the U.S.
PDF Text as PDF-File
04.01.2006Fresenius AG Announces Debt Tender Offer
04.01.2006Fresenius AG specifies plans for a bond issue in January
PDF Text as PDF-File
Home  >  Investor Relations  >  News  >  Investor News  >  2006